Apixaban for Myeloproliferative Neoplasm
(AIRPORT-MPN Trial)
Trial Summary
What is the purpose of this trial?
This trial is testing apixaban, a new blood thinner, to see if it is better and safer than aspirin for preventing blood clots in patients with myeloproliferative neoplasms (MPNs). MPN patients are at high risk for blood clots, which can lead to serious health problems. Apixaban helps by thinning the blood to prevent these clots.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are currently on any medication that interacts with apixaban.
What data supports the effectiveness of the drug Apixaban for Myeloproliferative Neoplasm?
Research suggests that direct oral anticoagulants (DOACs) like Apixaban may be effective and safe for patients with myeloproliferative neoplasms (MPNs), as they showed a low incidence of thrombotic events in a study. Additionally, low-dose aspirin, a component of the treatment, has been effective in preventing vascular complications in similar conditions.12345
Is Apixaban generally safe for use in humans?
Apixaban, also known as Eliquis, is generally considered safe for use in humans, with studies showing it has a lower risk of bleeding compared to some other blood thinners. It has been well tolerated in trials for conditions like venous thromboembolism and atrial fibrillation, with fewer major bleeding events compared to other treatments.678910
How does the drug Apixaban differ from other treatments for myeloproliferative neoplasms?
Apixaban is a direct oral anticoagulant (DOAC) that may offer a novel approach for treating myeloproliferative neoplasms by preventing thrombotic events, unlike the standard low-dose aspirin treatment. While aspirin is commonly used to prevent blood clots, Apixaban's unique mechanism as a DOAC could provide an alternative with potentially different safety and efficacy profiles.123411
Research Team
Aurelien Delluc, MD, PhD
Principal Investigator
The Ottawa Hospital
Miriam Kimpton, MD
Principal Investigator
The Ottawa Hospital
Eligibility Criteria
This trial is for adults over 18 with specific blood disorders (PV, JAK2ET or pre-fibrotic MF) who can follow the study plan. It's not for those allergic to apixaban or aspirin, needing other blood thinners, with low platelets/Von Willebrand disease, kidney/liver issues, on conflicting meds, pregnant/breastfeeding women or without effective contraception.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either apixaban or aspirin for at least 6 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Apixaban
- Aspirin
Apixaban is already approved in European Union, United States for the following indications:
- Deep vein thrombosis
- Pulmonary embolism
- Nonvalvular atrial fibrillation
- Deep vein thrombosis
- Pulmonary embolism
- Nonvalvular atrial fibrillation
- Stroke prevention
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ottawa Hospital Research Institute
Lead Sponsor
Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network
Collaborator
the Association médicale universitaire de l'Hôpital Montfort (AMUHM)
Collaborator
Canadian Society of Hematology
Collaborator
Canadian Hematology Society
Collaborator